B型主动脉夹层胸主动脉腔内修复术后二次主动脉干预的发生率、预测因素及意义
单中心回顾性分析2010年1月至2017年5月860例B型主动脉夹层行胸主动脉腔内修复术患者,107例(12.4%)需二次主动脉干预。二次干预后30天死亡率为4.7%。慢性期行胸主动脉腔内修复术、最大主动脉直径和弓部受累是二次干预的预测因素。
要点
- 二次主动脉干预的主要指征为入口血流(54.2%)、近端或远端主动脉瘤样扩张(24.3%)。
- 慢性期行胸主动脉腔内修复术患者二次干预发生率显著高于急性期和亚急性期。
- 二次干预后30天死亡率4.7%,腔内治疗2.6% vs 开放手术9.7%(p=0.145)。
核心结论
- 慢性期B型主动脉夹层患者行胸主动脉腔内修复术应重新考虑。
- 近端进展者开放手术更可取,远端病变者腔内治疗更合适。
- 胸主动脉腔内修复术后密切监测和及时再干预是必要的,以防止灾难性并发症。
研究设计与样本
- 单中心回顾性研究,纳入2010年1月至2017年5月860例接受胸主动脉腔内修复术的B型主动脉夹层患者。
- 107例(12.4%)患者需二次主动脉干预,其中腔内治疗76例,开放手术31例。
主要发现
- 二次主动脉干预后总体30天死亡率为4.7%(5例):腔内治疗2例(2.6%)vs 开放手术3例(9.7%),p=0.145。
- 有二次干预与无二次干预患者累积生存率:3年86.3%±3.6% vs 95.7%±0.8%,5年82.0%±4.2% vs 92.2%±1.1%(log-rank p<0.001)。
- 二次干预发生率:急性期11.6% vs 亚急性期9.6% vs 慢性期27.8%,p<0.001。
- 多因素回归分析显示,慢性期行胸主动脉腔内修复术(HR=1.73,95%CI 1.03-2.90;p=0.039)、最大主动脉直径(HR=1.05,95%CI 1.04-1.07;p<0.001)和弓部受累(HR=1.48,95%CI 1.01-2.18;p=0.048)是二次干预的预测因素。
- 调整混杂因素后,最大主动脉直径是预后的唯一危险因素。
临床怎么用
- 作者认为慢性期B型主动脉夹层患者行胸主动脉腔内修复术应重新考虑。
- 作者建议近端进展者开放手术更可取,远端病变者腔内治疗更合适。
- 作者认为胸主动脉腔内修复术后密切监测和及时再干预是必要的。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary aortic intervention (SAI) following thoracic endovascular aortic repair (TEVAR) is not uncommon. However, a satisfactory management system has not been established for these patients. We aimed to report our single-center experience with SAI after prior TEVAR for type B aortic dissection (TBAD). METHODS: From January 2010 to May 2017, 860 eligible patients with TBAD underwent TEVAR. One hundred seven (12.4%) patients required SAI, either endovascularly (n=76) or surgically (n=31). The main indications for SAI were entry flow (n=58 [54.2%]), aneurysm expansion of the proximal or remote aorta (n=26 [24.3%]), retrograde type A aortic dissection (n=11 [10.3%]), distal stent-graft-induced new entry tear (n=6 [5.6%]), and stent migration (n=4 [3.7%]). The Kaplan-Meier curves were generated to determine the degree of freedom from SAI and the prognosis. Cox proportional hazards were used to screen for risk factors for SAI and poor prognosis. RESULTS: The overall 30-day mortality rate after SAI was 4.7% (n=5): endovascular (n=2 [2.6%]) vs open surgery (n=3 [9.7%]; p=0.145). The cumulative survival rates with or without SAI were 86.3%±3.6% vs 95.7%±0.8% at 3 years and 82.0%±4.2% vs 92.2%±1.1% at 5 years, respectively (log-rank p<0.001). Although no significant difference in survival was observed, the incidence of SAI was significantly greater in patients who underwent TEVAR during the chronic phase (acute [11.6%] vs subacute [9.6%] vs chronic [27.8]; p<0.001). Multivariate regression analysis revealed that prior TEVAR in the chronic phase (hazard ratio [HR]=1.73, 95% confidence interval [CI]=1.03-2.90; p=0.039), maximum aortic diameter (HR=1.05, 95% CI=1.04-1.07; p<0.001), and arch involvement (HR=1.48, 95% CI=1.01-2.18; p=0.048) were predictors of the incidence of SAI. In addition, the maximum aortic diameter was demonstrated to be the only risk factor for prognosis after adjusting for confounding factors. CONCLUSIONS: Thoracic endovascular aortic repair for chronic TBAD patients should be reconsidered. Open surgery is preferable for those with proximal progression, whereas endovascular treatment is more suitable for distal lesions. Close surveillance and timely reintervention after TEVAR, whether via endovascular techniques or open surgery, are necessary to prevent devastating complications.Clinical ImpactThe management of patients with type B aortic dissection (TBAD) after thoracic endovascular aortic repair (TEVAR) is challenging. We summarized our single-center experience regarding secondary aortic intervention after TEVAR for TBAD. We found that TEVAR for chronic TBAD patients should be carefully evaulated, and open surgery is recommended for those with proximal progession, while endovascular treatment is more preferable for distal lesions.
引用
- Wang J, Hu X, Liu J, et al. Incidence, Predictors, and Implications of Secondary Aortic Intervention Following Thoracic Endovascular Aortic Repair for Type B Dissection. J Endovasc Ther. 2024. PMID: 38804527. doi:10.1177/15266028241255549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。